Original Research
Published on 26 May 2025
Studies on nanoprotein vaccine alleviating symptoms of mice allergic to rFel d 1
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1524929
- 902 views
Type at least 3 characters
2,955 articles
Study Protocol
Published on 23 May 2025
Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1568778
- 1,555 views
Editorial
Published on 23 May 2025
Editorial: Innate immune response and interaction with adaptive immunity: role in tuberculosis immunology/vaccinology
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1609680
- 858 views
Review
Published on 22 May 2025
Applying computational protein design to therapeutic antibody discovery - current state and perspectives
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1571371
- 2,743 views
Original Research
Published on 22 May 2025
Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1569151
- 1,388 views
Systematic Review
Published on 22 May 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1581153
- 4,262 views
Review
Published on 21 May 2025
Peptide vaccines: an innovative therapeutic approach against antibiotic-resistant bacterial infections
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1567584
- 1,387 views
Brief Research Report
Published on 21 May 2025
Ultra-sensitive in situ detection of intracellular Mycobacterium tuberculosis with CRISPR/Cas12a
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1597654
- 966 views
Original Research
Published on 21 May 2025
Prime-boost vaccination with chimeric antigens adjuvanted in Montanide™ ISA50 V2 confers protection against experimental Lepeophtheirus salmonis infestation in Atlantic salmon (Salmo salar L.)
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1570948
- 828 views
Review
Published on 21 May 2025
Methods integrating innate and adaptive immune responses in human in vitro immunization assays
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1584852
- 1,050 views
Original Research
Published on 20 May 2025
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1571835
- 1,541 views
Original Research
Published on 20 May 2025
An integrated mutation-based immunoinformatic approach incorporating variability in epitopes: a study based on HIV subtype C
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1540253
- 867 views
Original Research
Published on 20 May 2025
Humoral and cellular immune responses in cattle upon Clostridium chauvoei vaccination and challenge
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1584168
- 1,057 views
Original Research
Published on 19 May 2025
Unveiling reverse vaccinology and immunoinformatics toward Saint Louis encephalitis virus: a ray of hope for vaccine development
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1576557
- 1,529 views
Systematic Review
Published on 19 May 2025
Immune mechanisms mediating the heterologous effects of BCG vaccination: a systematic review
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1567111
- 2,052 views
Original Research
Published on 19 May 2025
Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 ‘Patria’ vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1565934
- 1,952 views